Combination therapy for pulmonary hypertension
AssigneeVivus, Inc.
InventorsLeo GU, Paul C. NAKAGAKI, Narinder S. BANAIT
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for the treatment of pulmonary hypertension using combination therapy. The combination therapy comprises a compound that increases BMPR2 signaling (BMPR2 activator) in combination with at least one other agent for the treatment of pulmonary hypertension. In certain aspects, the BMPR2 activator can be tacrolimus or a pharmaceutically acceptable solvate, salt, or prodrug thereof.
Claims20
A method of treating or preventing pulmonary hypertension in a patient in need thereof, the method comprising:
- administering a therapeutically effective amount of a compound that increases BMPR2 signaling (BMPR2 activator) to the patient with pulmonary hypertension in combination with another active agent effective for treatment of the pulmonary hypertension condition or a condition related thereto.
A method of treating or preventing pulmonary arterial hypertension in a patient in need thereof, the method comprising:
- administering a therapeutically effective amount of tacrolimus or a pharmaceutically acceptable solvate or salt thereof to the patient with pulmonary arterial hypertension in combination with another active agent effective for treatment of the pulmonary hypertension condition or a condition related thereto.
A method of treating pulmonary hypertension in a patient in need thereof, the method comprising:
- administering a therapeutically effective amount of a compound that increases BMPR2 signaling (BMPR2 activator) to the patient with pulmonary arterial hypertension.
Dependencies are inferred from the claim text.